Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
35.86 EUR | +0.49% |
|
+0.45% | -5.58% |
Jun. 19 | FMC FRESENIUS MEDICAL CARE AG & CO KGAA : UBS sticks Neutral | ZD |
Jun. 14 | FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Gets a Sell rating from Jefferies | ZD |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company is in debt and has limited leeway for investment
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.58% | 11.24B | A- | ||
+18.11% | 83.73B | C+ | ||
-27.15% | 72.21B | B- | ||
-0.99% | 26.2B | - | C+ | |
-10.81% | 17.09B | B | ||
+1.60% | 17.18B | A- | ||
-0.90% | 15.18B | A- | ||
+76.72% | 13.59B | C- | ||
+77.64% | 13.11B | C+ | ||
-23.68% | 12.92B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FME Stock
- Ratings Fresenius Medical Care AG